SCHEMBL265442

SCHEMBL265442

Cc1cccc(/C=N/NC(=O)c2ccccc2NC(=O)c2cccc(F)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.56
NPC1 O15118 7/20 0.56
PKM P14618 5/20 0.56
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 5/20 0.54
POLB P06746 4/20 0.54
TDP1 Q9NUW8 2/20 0.54
ALDH1A1 P00352 1/20 0.53
KMT2A Q03164 8/20 0.52
MEN1 O00255 6/20 0.52
CTDSP1 Q9GZU7 1/20 0.52
GUSB P08236 1/20 0.52
LMNA P02545 1/20 0.51
GAA P10253 2/20 0.50
MGAM O43451 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265443 1.00 RAB9A (0.56) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL266683 0.92 NPC1 (0.62) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL266682 0.92 NPC1 (0.62) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL268720 0.91 RAB9A (0.64) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL266421 0.91 RAB9A (0.61) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL268721 0.91 RAB9A (0.64) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL266420 0.91 RAB9A (0.61) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL266071 0.89 NPSR1 (0.62) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL266072 0.89 NPSR1 (0.62) RAB9ANPC1PKMMAPTSMN1; SMN2
SCHEMBL268644 0.89 RAB9A (0.58) RAB9ANPC1PKMMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 RAB9A 883/4885NPC1 102/4885PKM 1697/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885NPC1 115/4885PKM 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.